Seagen Stock Price, News & Analysis

sgen NASDAQ

Company Description

Seagen (NASDAQ: sgen) is a publicly traded biological product (except diagnostic) manufacturing company in the Manufacturing sector.

sgen stock has declined 100.0% over the past year.

This page provides a comprehensive overview of sgen stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$0.0

Market Cap

188.7M

Shares outstanding

Seagen (sgen) stock. Over the past 12 months, the stock has lost 100.0%.

Latest News

View All

December 14, 2023

0.00%

Pfizer Completes Acquisition of Seagen

acquisition

December 12, 2023

+3.29%

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

acquisition

December 11, 2023

+1.20%

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

clinical trial

December 6, 2023

-0.01%

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

November 30, 2023

-0.23%

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

fda approval

November 3, 2023

+0.10%

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

clinical trial

Seagen has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include acquisition, clinical trial, fda approval, earnings. View all sgen news →

SEC Filings

View All

No SEC filings available for sgen.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

sgen Company Profile & Sector Positioning

Seagen (sgen) operates in the Biological Product (except Diagnostic) Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.